ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder
Newswise — SAN DIEGO ― The targeted therapy bezuclastinib was safe and rapidly reduced markers of disease burden while also improving symptoms for patients with a rare blood…
Read more ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder